BioMark Diagnostics Establishes African Market Presence Through Strategic Tunisia Healthcare Partnership
BioMark Diagnostics (OTCQB: BMKDF) has entered a strategic Expression of Interest agreement with SAMA CONSULTING SARL to implement its liquid biopsy platform for lung cancer detection in Tunisia. The partnership aims to address the critical healthcare need in North Africa, where lung cancer is a leading cause of cancer-related deaths.
The collaboration will begin with a proof-of-concept trial in October 2025, evaluating the platform's performance within Tunisia's healthcare system. Following successful implementation, BioMark plans to expand across North Africa, potentially reaching a market of over 90 million people across Tunisia, Algeria, Morocco, and seven additional countries.
BioMark Diagnostics (OTCQB: BMKDF) ha siglato un accordo strategico di manifestazione d'interesse con SAMA CONSULTING SARL per implementare la sua piattaforma di biopsia liquida per la rilevazione del cancro ai polmoni in Tunisia. La partnership mira a rispondere a un bisogno sanitario critico nel Nord Africa, dove il cancro al polmone è una delle principali cause di decessi per tumore.
La collaborazione inizierà con una prova di concetto in ottobre 2025, valutando le prestazioni della piattaforma nel contesto del sistema sanitario tunisino. In caso di esito positivo, BioMark intende espandersi nel Nord Africa, con l'obiettivo di raggiungere potenzialmente un mercato di oltre 90 milioni di persone tra Tunisia, Algeria, Marocco e altri sette paesi.
BioMark Diagnostics (OTCQB: BMKDF) ha firmado un acuerdo estratégico de manifestación de interés con SAMA CONSULTING SARL para implementar su plataforma de biopsia líquida para la detección del cáncer de pulmón en Túnez. La asociación pretende atender una necesidad sanitaria crítica en el norte de África, donde el cáncer de pulmón es una de las principales causas de muerte por cáncer.
La colaboración comenzará con un ensayo de prueba de concepto en octubre de 2025, evaluando el rendimiento de la plataforma en el sistema sanitario tunecino. Tras una implementación exitosa, BioMark planea expandirse por el norte de África con el potencial de alcanzar un mercado de más de 90 millones de personas en Túnez, Argelia, Marruecos y otros siete países.
BioMark Diagnostics (OTCQB: BMKDF)는 SAMA CONSULTING SARL과 튀니지에서 폐암 검출을 위한 액체생검 플랫폼 도입을 위한 전략적 관심표명 계약을 체결했습니다. 이 파트너십은 폐암이 암 관련 사망의 주요 원인인 북아프리카의 중대한 보건 문제를 해결하는 것을 목표로 합니다.
협력은 2025년 10월 개념검증 시험으로 시작되어 튀니지 보건 시스템 내에서 플랫폼의 성능을 평가합니다. 성공적으로 도입되면 BioMark는 북아프리카 전역으로 확장할 계획이며 튀니지, 알제리, 모로코 및 기타 7개국을 포함해 9천만 명 이상 규모의 시장에 도달할 잠재력이 있습니다.
BioMark Diagnostics (OTCQB: BMKDF) a conclu un accord stratégique d'expression d'intérêt avec SAMA CONSULTING SARL pour déployer sa plateforme de biopsie liquide destinée à la détection du cancer du poumon en Tunisie. Le partenariat vise à répondre à un besoin sanitaire critique en Afrique du Nord, où le cancer du poumon est l'une des principales causes de mortalité par cancer.
La collaboration débutera par un essai de preuve de concept en octobre 2025, évaluant les performances de la plateforme au sein du système de santé tunisien. En cas de succès, BioMark prévoit de s'étendre à travers l'Afrique du Nord, avec la possibilité d'atteindre un marché de plus de 90 millions de personnes couvrant la Tunisie, l'Algérie, le Maroc et sept autres pays.
BioMark Diagnostics (OTCQB: BMKDF) hat eine strategische Absichtserklärung mit SAMA CONSULTING SARL geschlossen, um seine Liquid-Biopsy-Plattform zur Detektion von Lungenkrebs in Tunesien einzuführen. Die Partnerschaft zielt darauf ab, einen dringenden gesundheitlichen Bedarf in Nordafrika zu adressieren, wo Lungenkrebs eine der führenden krebsbedingten Todesursachen ist.
Die Zusammenarbeit beginnt mit einer Machbarkeitsstudie im Oktober 2025, in der die Leistungsfähigkeit der Plattform im tunesischen Gesundheitssystem bewertet wird. Bei erfolgreicher Umsetzung plant BioMark eine Ausweitung in Nordafrika und könnte dabei einen Markt von über 90 Millionen Menschen in Tunesien, Algerien, Marokko und sieben weiteren Ländern erreichen.
- None.
- Initial implementation limited to Tunisia market only
- Success depends on proof-of-concept trial results
- Regulatory compliance across multiple countries may present challenges
Proof-of-Concept Trial Opens Door to 90+ Million Population Across North Africa and Francophone Markets
Vancouver, British Columbia--(Newsfile Corp. - August 12, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark"), a leading developer of liquid biopsy tests for early cancer detection, announced today a strategic Expression of Interest (EOI) agreement with SAMA CONSULTING SARL ("SAMA CONSULTING") to explore the clinical application of BioMark's innovative liquid biopsy platform for lung cancer detection initially in Tunisia and later across the broader North African region.
Partnership Addresses Critical Healthcare Need
Lung cancer represents a leading cause of cancer-related mortality in Tunisia, creating an urgent need for innovative, accessible, and accurate early detection solutions. This collaboration positions BioMark's cutting-edge liquid biopsy technology as a potential game-changer in national cancer screening healthcare initiatives across North Africa.
"This collaboration represents a significant milestone in our mission to make advanced cancer detection accessible globally," said Rashid Bux, Chief Executive Officer of BioMark Diagnostics. "Tunisia's commitment to improving cancer outcomes, combined with our proven liquid biopsy technology, creates an exceptional opportunity to transform early detection capabilities in that region."
Proof-of-Concept Trial to Validate Clinical Utility
The collaboration will commence with a proof-of-concept trial. The trial, scheduled to begin in October 2025, will evaluate the performance, accuracy, and clinical utility of BioMark's proprietary liquid biopsy platform within the Tunisian healthcare system.
Key objectives of the partnership include:
Assessing the technology's effectiveness in the target population
Advancing publication of clinical data to support broader adoption
Evaluating integration potential with national screening programs
Strategic Expansion into Emerging Markets
This partnership marks BioMark's strategic entry into the North African market, demonstrating the company's commitment to expanding access to advanced cancer diagnostics in emerging healthcare markets. The collaboration leverages SAMA CONSULTING's local expertise and clinical connections to facilitate rapid implementation and regulatory compliance.
"We are excited to partner with BioMark to bring this revolutionary technology to Tunisia and later to 90+ million across Tunisia, Algeria, Morocco, and 7 additional countries," said Ayoub Hitana, representing SAMA CONSULTING SARL. "Early detection is crucial for improving cancer outcomes, and this liquid biopsy technology has the potential to significantly impact patient survival rates in our region."
Both parties agree that Tunisia's healthcare system could serve as an ideal testing ground for BioMark's technology, with potential for expansion throughout North Africa and the Middle East. The successful implementation of this collaboration could establish BioMark as a leader in emerging market cancer diagnostics.
Timing
The collaboration follows an ambitious timeline with October 2025 as the planned commencement of proof-of-concept trials and initial clinical data collection. Completion is anticipated by the end of December 2025.
Regulatory Compliance and Quality Assurance
Both organizations are committed to ensuring all activities comply with Tunisian healthcare regulations, international clinical trial standards, and data privacy requirements. The partnership operates under comprehensive Non-Disclosure Agreements to protect proprietary information while facilitating effective collaboration.
About SAMA CONSULTING SARL
SAMA CONSULTING SARL is a Tunisian consulting firm specializing in healthcare innovation and clinical research facilitation. The company provides expertise in regulatory compliance, clinical trial management, and healthcare system integration across North Africa and Francophone Africa. In addition, medical laboratories in Tunisia, Algeria, Morocco, Mauritania, the Ivory Coast, Togo, Guinea, Mali, Cameroon, and Senegal use SAMA's software solutions.
About BioMark Diagnostics Inc.
BioMark Diagnostics Inc. is a leading developer of liquid biopsy tests for the early detection of cancer that leverages the power of metabolomics and machine learning algorithms. The company's proprietary technology utilizes a simple blood draw to detect the presence of cancer-associated biomarkers, enabling earlier diagnosis and improved patient outcomes. The technology can also be used for measuring response to treatment and potentially for serial monitoring of cancer survivors. BioMark is committed to developing innovative and accessible diagnostic solutions to address unmet medical needs in oncology.
Further information about BioMark is available under its profile on the SEDAR+ website www.sedarplus.ca and the CSE website https://thecse.com/.
For further information on BioMark, please contact:
Rashid Ahmed Bux
President & CEO
BioMark Diagnostics Inc.
Tel. 604-370-0779
Email: info@biomarkdiagnostics.com
Forward-Looking Information:
This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of BioMark. Forward-looking information is based on certain key expectations and assumptions made by the management of BioMark. Although BioMark believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because BioMark can give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the date of this press release. BioMark disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events, or results or otherwise, other than as required by applicable securities laws.
The CSE has not reviewed, approved, or disapproved of the content of this press release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/262111
FAQ
What is the strategic partnership between BioMark Diagnostics (BMKDF) and SAMA CONSULTING SARL?
When will BioMark Diagnostics (BMKDF) begin its proof-of-concept trial in Tunisia?
What is the potential market size for BioMark's (BMKDF) expansion in North Africa?
What are the key objectives of BioMark's (BMKDF) Tunisia partnership?
How will BioMark (BMKDF) ensure regulatory compliance in Tunisia?
